Drug Discovery Informatics Market Report Research Report - Forecast Till 2027

Drug Discovery Informatics Market Share, Trends And Size Analysis By Product (Discovery Informatics, Development Informatics), Mode (In-House Informatics), Service (Clinical Trial Data Management, Molecular Modeling), & End User—Forecast Till 2027

ID: MRFR/HC/6360-HCR | February 2021 | Region: Global | 90 pages

Drug Discovery Informatics Market Scenario


Drug Discovery Informatics Market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 1,680.6 million in 2017 and is projected to grow at a CAGR of 11.5% during the forecast period. Drug discovery and development is a highly intricate process requiring the generation of very large amounts of data and information. Large amounts of data are generated using a variety of innovative technologies, and the limiting step is accessing, searching and integrating this data. The current approaches to collect information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. However, the world is on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are undergoing a paradigm shift. Mining and integration of domain-specific information such as chemical and genomic data will continue to develop in the near future. Drug discovery is a functional process in pharmaceutical and biotechnology companies. It involves different steps and procedures that depend on in-silico tools for reducing the complexity of a process.

Some of the factors driving the market growth are a rising worldwide focus on drug discovery, growing need to control drug discovery and development costs, growth in R&D expenditure, and increasing burden of chronic diseases. For instance, according to the World Health Organization (WHO), in 2001, chronic diseases contributed around 60% of the 56.5 million total reported deaths across the world and approximately 46% of the global burden of disease, which is projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide. On the other hand, high pricing and setup cost of informatics software is anticipated to restrict the market growth during the forecast period.


Segmentation


The drug discovery informatics market has been segmented into product, mode, service, end user, and region.


By product, the market has been segmented into discovery informatics and development informatics.


On the basis of mode, the market has been divided into in-house informatics and outsourced informatics. 


By service, the market has been classified into sequencing and target data analysis, docking, molecular modeling, clinical trial data management, and others. The sequencing and target data analysis segment is expected to dominate the market over the forecast period due to rising application of informatics solutions in targeted analysis and a large amount of data generated during the drug discovery process.


Based on end user, the market has been categorized into pharmaceutical and biotechnology industries, contract research organizations (CROs), and others.


The drug discovery informatics market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The drug discovery informatics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. 


The European drug discovery informatics market has been segmented into Western Europe and Eastern Europe. The Western Europe drug discovery informatics global market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The drug discovery informatics global market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The drug discovery informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Few of the spearheads in the drug discovery informatics market are Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes.


Regional Market Summary
Drug Discovery Informatics Market Share
Global Drug Discovery Informatics Market Share (%), by Region, 2017

Geographically, the Americas spearheaded the drug discovery informatics market in 2017. This is owing to the presence of major market value participants (Thermo Fisher Scientific, Inc., PerkinElmer, Inc., International Business Machines Corporation) and sophisticated healthcare infrastructure, flourishing pharmaceutical and biotechnology industries, and developments of next-generation sequencing and chemical laboratories in the US and Canada.


Europe would be the second largest contributor in terms of value during next five years attributed to the financial support provided by the government for research and development in drugs, growth in the therapeutic discovery ventures and activities carried out by research and academic institutes, universities, and other centers.


Asia-Pacific is expected to represent profitable market growth from 2018 to 2023 owing to growing geriatric population coupled with rising prevalence of chronic diseases, increasing awareness and high adoption of drug discovery informatics, and surging number of clinical trials studies in the region. For instance, Asia-Pacific offers a substantial cost saving advantage, with savings ranging from 50% to 80% of the cost in comparison with the developed nations, thereby resulting into a rise in the volume of clinical trials being conducted in this region.


The drug discovery informatics market in the Middle East & Africa would witness the modest market growth rate from 2018 to 2023. The Middle East and North Africa (MENA) region constitutes 2% of global pharmaceutical sales. Rampant growth in population has fueled drug demand especially for higher-yield pharmaceutical products attracting the attention of multinational pharmaceutical companies in the MENA region.


Drug Discovery Informatics Market, by Product



  • Discovery Informatics

  • Development Informatics


Drug Discovery Informatics Market, by Mode



  • In-house Informatics

  • Outsourced Informatics


Global Drug Discovery Informatics Market, by Service



  • Sequencing and Target Data Analysis

  • Docking

  • Molecular Modeling

  • Clinical Trial Data Management

  • Others


Drug Discovery Informatics Market, by End User



  • Pharmaceutical and Biotechnology Industries

  • Contract Research Organizations (CROs)

  • Others


Drug Discovery Informatics Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe



  • Eastern Europe

    • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Drug Discovery Informatics Market, by Key Players



  • Thermo Fisher Scientific, Inc.

  • PerkinElmer, Inc.

  • Certara, L.P.

  • Infosys Limited

  • Novo Informatics Pvt. Ltd.

  • Collaborative Drug Discovery Inc.

  • Selvita

  • Charles River Laboratories, Inc.

  • International Business Machines Corporation

  • Jubilant Life Sciences Ltd.

  • IO Informatics, Inc.

  • GVK Biosciences Private Limited

  • Dassault Systèmes


Intended Audience



  • Drug discovery informatics providers

  • Venture capitalists

  • Pharmaceutical companies

  • Biotechnology companies

  • Research and academic institutes

  • Government associations

  • Association and government bodies

  • Market research and consulting service providers

  • Corporate entities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2017: USD 1,680.6 Million
  • 2027: Significant Value
  •   CAGR   11.5% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Product, Mode, Service, End user,
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising worldwide focus on drug discovery
  • Growing need to control drug discovery and development costs
  • Growth in R&D expenditure
  • Increasing burden of chronic diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Drug discovery informatics market was valued at more than USD 1.6 billion in 2017.

    Drug discovery informatics market is expected to exhibit a solid 11.5% CAGR over the forecast period from 2018 to 2023.

    The increasing investment in drug discovery applications is likely to be a major driver for the global drug discovery informatics market.

    The Americas spearhead the global drug discovery informatics market, followed by Europe.

    Leading players in the drug discovery informatics market include Thermo Fisher Scientific, Infosys, Certara, Selvita, and Jubilant Life Sciences, among others.

    Table of Contents:

    Chapter 1 Report Prologue

    Chapter 2 Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3 Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4 Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Detection Technique Trends & Assessment

    Chapter 5 Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6 Global Drug Discovery Informatics Market, by Product

    6.1 Introduction

    6.2 Discovery Informatics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Development Informatics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7 Global Drug Discovery Informatics Market, by Mode

    7.1 Introduction

    7.2 In-House Informatics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Outsourced Informatics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8 Global Drug Discovery Informatics Market, by Service

    8.1 Introduction

    8.2 Sequencing and Target Data Analysis

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Docking

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Molecular Modeling

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5 Clinical Trial Data Management

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6 Others

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 9 Global Drug Discovery Informatics Market, by End User

    9.1 Introduction

    9.2 Pharmaceutical and Biotechnology Industries

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.3 Contract Research Organizations (CROs)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.4 Others

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 10 Global Drug Discovery Informatics Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Developments & Strategies

    Chapter 12 Company Profiles

    12.1 Thermo Fisher Scientific, Inc.

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financial Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.1.6 Key Strategies

    12.2 PerkinElmer, Inc.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.2.6 Key Strategies

    12.3 Certara, L.P.

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Developments

    12.3.5 SWOT Analysis

    12.3.6 Key Strategies

    12.4 Infosys Limited

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Developments

    12.4.5 SWOT Analysis

    12.4.6 Key Strategies

    12.5 Novo Informatics Pvt. Ltd.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.5.6 Key Strategies

    12.6 Collaborative Drug Discovery Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.6.6 Key Strategies

    12.7 Selvita

    12.7.1 Company Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.7.6 Key Strategies

    12.8 Charles River Laboratories, Inc.

    12.8.1 Company Overview

    12.8.2 Product Overview

    12.8.3 Financial Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.8.6 Key Strategies

    12.9 International Business Machines Corporation

    12.9.1 Company Overview

    12.9.2 Product Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.9.6 Key Strategies

    12.10 Jubilant Life Sciences Ltd.

    12.10.1 Company Overview

    12.10.2 Product Overview

    12.10.3 Financial Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.10.6 Key Strategies

    12.11 IO Informatics, Inc.

    12.11.1 Company Overview

    12.11.2 Product Overview

    12.11.3 Financial Overview

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.11.6 Key Strategies

    12.12 GVK Biosciences Private Limited

    12.12.1 Company Overview

    12.12.2 Product Overview

    12.12.3 Financial Overview

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.12.6 Key Strategies

    12.13 Dassault Systèmes

    12.13.1 Company Overview

    12.13.2 Product Overview

    12.13.3 Financial Overview

    12.13.4 Key Developments

    12.13.5 SWOT Analysis

    12.13.6 Key Strategies

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Drug Discovery Informatics Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Global Drug Discovery Informatics Market Synopsis, 2020–2027

    Table 2 Global Drug Discovery Informatics Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Drug Discovery Informatics Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 5 Global Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 6 Global Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 7 Global Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 8 North America: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 9 North America: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 10 North America Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 11 North America: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 12 US: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 13 US: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 14 US: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 15 US: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 16 Canada: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 17 Canada: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 18 Canada: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 19 Canada: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 20 Latin America: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 21 Latin America: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 22 Latin America: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 23 Latin America: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 24 Europe: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 25 Europe: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 26 Europe: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 27 Europe: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 28 Western Europe: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 29 Western Europe: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 30 Western Europe: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 31 Western Europe: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 32 Eastern Europe: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 34 Eastern Europe: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 35 Eastern Europe: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 36 Asia-Pacific: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 37 Asia-Pacific: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 38 Asia-Pacific: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 39 Asia-Pacific: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    Table 40 Middle East & Africa: Drug Discovery Informatics Market, by Product, 2020–2027 (USD Million)

    Table 41 Middle East & Africa: Drug Discovery Informatics Market, by Mode, 2020–2027 (USD Million)

    Table 42 Middle East & Africa: Drug Discovery Informatics Market, by Service, 2020–2027 (USD Million)

    Table 43 Middle East & Africa: Drug Discovery Informatics Market, by End User, 2020–2027 (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Drug Discovery Informatics Market

    Figure 3 Segmentation Market Dynamics for Global Drug Discovery Informatics Market

    Figure 4 Global Drug Discovery Informatics Market Share, by Product, 2020

    Figure 5 Global Drug Discovery Informatics Market Share, by Mode, 2020

    Figure 6 Global Drug Discovery Informatics Market Share, by Service, 2020

    Figure 7 Global Drug Discovery Informatics Market Share, by End User, 2020

    Figure 8 Global Drug Discovery Informatics Market Share, by Region, 2020

    Figure 9 North America: Drug Discovery Informatics Market Share, by Country, 2020

    Figure 10 Europe: Drug Discovery Informatics Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Drug Discovery Informatics Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Drug Discovery Informatics Market Share, by Country, 2020

    Figure 13 Global Drug Discovery Informatics Market: Company Share Analysis, 2020 (%)

    Figure 14 Thermo Fisher Scientific, Inc.: Key Financials

    Figure 15 Thermo Fisher Scientific, Inc.: Segmental Revenue

    Figure 16 Thermo Fisher Scientific, Inc.: Geographical Revenue

    Figure 17 PerkinElmer, Inc.: Key Financials

    Figure 18 PerkinElmer, Inc.: Segmental Revenue

    Figure 19 PerkinElmer, Inc.: Geographical Revenue

    Figure 20 Certara, L.P.: Key Financials

    Figure 21 Certara, L.P.: Segmental Revenue

    Figure 22 Certara, L.P.: Geographical Revenue

    Figure 23 Infosys Limited: Key Financials

    Figure 24 Infosys Limited: Segmental Revenue

    Figure 25 Infosys Limited: Geographical Revenue

    Figure 26 Novo Informatics Pvt. Ltd.: Key Financials

    Figure 27 Novo Informatics Pvt. Ltd.: Segmental Revenue

    Figure 28 Novo Informatics Pvt. Ltd.: Geographical Revenue

    Figure 29 Collaborative Drug Discovery Inc.: Key Financials

    Figure 30 Collaborative Drug Discovery Inc.: Segmental Revenue

    Figure 31 Collaborative Drug Discovery Inc.: Geographical Revenue

    Figure 32 Selvita: Key Financials

    Figure 33 Selvita: Segmental Revenue

    Figure 34 Selvita: Geographical Revenue

    Figure 35 Charles River Laboratories, Inc.: Key Financials

    Figure 36 Charles River Laboratories, Inc.: Segmental Revenue

    Figure 37 Charles River Laboratories, Inc.: Geographical Revenue

    Figure 38 International Business Machines Corporation: Key Financials

    Figure 39 International Business Machines Corporation: Segmental Revenue

    Figure 40 International Business Machines Corporation: Geographical Revenue

    Figure 41 Jubilant Life Sciences Ltd.: Key Financials

    Figure 42 Jubilant Life Sciences Ltd.: Segmental Revenue

    Figure 43 Jubilant Life Sciences Ltd.: Geographical Revenue

    Figure 44 IO Informatics, Inc.: Key Financials

    Figure 45 IO Informatics, Inc.: Segmental Revenue

    Figure 46 IO Informatics, Inc.: Geographical Revenue

    Figure 47 GVK Biosciences Private Limited: Key Financials

    Figure 48 GVK Biosciences Private Limited: Segmental Revenue

    Figure 49 GVK Biosciences Private Limited: Geographical Revenue

    Figure 50 Dassault Systèmes: Key Financials

    Figure 51 Dassault Systèmes: Segmental Revenue

    Figure 52 Dassault Systèmes: Geographical Revenue



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.